ABSTRACT
A case report of a twenty-year-old man with quiescent, idiopathic intermediate uveitis in his right eye treated with systemic corticosteroids and persistent cystoid macular edema, admitted for further treatment due to chronic reduction in visual acuity, is presented. A therapy involving intravitreal injections of ranibizumab (Lucentis), followed by bevacizumab (Avastin) was started, leading to transient improvement of visual acuity and edema reduction confirmed in optical coherent tomography. A de cision of switching to intravitreal aflibercept (Eylea) was made. After a single intravitreal injection of aflibercept, a complete and sustained resolution of macular edema was achieved. aflibercept, uveitis, cystoid macular edema.
Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Macular Edema/drug therapy , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Visual Acuity/drug effects , Bevacizumab , Drug Therapy, Combination , Follow-Up Studies , Humans , Injections, Intraocular , Macular Edema/complications , Male , Ranibizumab , Remission Induction , Treatment Outcome , Young AdultABSTRACT
Multifocal choroiditis and panuveitis (MCP) belong to white dot syndromes, which are an idiopathic inflammatory process damaging the retinal pigment epithelium and choriocapillaris. We observed fourteen patients with typical ocular changes for MCP (panuveitis with typical multiple yellow, white or gray focal lesions in fundus of the eye). In 8 patients typically were observed--glaucoma, cataract, macular edema. We applied topical drops (corticosteroids, antiglaucomatous), and in 5 patients oral encorton was necessary to include.
